NCT06269133 is a clinical trial of REGN2810 in Advanced Non-small Cell Lung Cancer, sponsored by Regeneron Pharmaceuticals.

Who is sponsoring NCT06269133?

NCT06269133 is sponsored by Regeneron Pharmaceuticals.

What drugs are being tested in NCT06269133?

Interventions in NCT06269133: REGN2810, Platinum-doublet chemotherapy.

What condition does NCT06269133 study?

NCT06269133 studies Advanced Non-small Cell Lung Cancer.

Is NCT06269133 still recruiting?

NCT06269133 is currently active, enrolled. Last updated 27 August 2025.

Last reviewed 2025-08-27 · How we verify

NCT06269133

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Active, enrolled Last updated 27 August 2025

What this trial tests

trial testing REGN2810 in Advanced Non-small Cell Lung Cancer in 1,000 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

21 February 2024

Primary endpoint
31 March 2027

23 June 2027

Quick facts

Lead sponsor	Regeneron Pharmaceuticals
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	21 February 2024
Primary completion	31 March 2027
Estimated completion	23 June 2027
Sites	1 location across United States

Drugs / interventions tested

REGN2810 — full drug profile →
Platinum-doublet chemotherapy

Conditions studied

Advanced Non-small Cell Lung Cancer — all drugs for Advanced Non-small Cell Lung Cancer →

Sponsor

Regeneron Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Advanced Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This multi-year cohort study will assess the real-world safety and effectiveness of 1L treatment with cemiplimab in combination with platinum-doublet chemotherapy across advanced NSCLC patient subgroups defined by age, sex, race, and ethnicity. Patients will be retrospectively identified from at least two US electronic health record (EHR)-based databases.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Emerging advances in drug delivery systems (DDSs) for optimizing cancer complications.
Li K, Guo B, Gu J, Ta N, et al · · 2025 · cited 8× · PMID 39759851 · DOI 10.1016/j.mtbio.2024.101375

Verify or expand the search:

Other trials of REGN2810

Trials testing the same drug.

NCT03409614 — Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer · Phase 3 · completed
NCT03198130 — An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Pati · Phase 1 · completed
NCT03002376 — An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Mela · Phase 1 · completed

Other recruiting trials for Advanced Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT06868732 — Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC · Phase 1 · recruiting
NCT06452277 — A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Particip · Phase 3 · recruiting
NCT06043973 — Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance · Phase 3 · recruiting
NCT05416775 — Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
NCT05420220 — Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer · Phase 2 · recruiting

Other Regeneron Pharmaceuticals trials

Trials by the same sponsor.

NCT07428369 — A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · Phase 2, PHASE3 · not yet recruiting
NCT07526116 — A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adul · Phase 1 · not yet recruiting
NCT07527923 — First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis · Phase 1 · not yet recruiting
NCT07527910 — A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD · Phase 2 · not yet recruiting
NCT07477704 — A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemi · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06269133 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Regeneron Pharmaceuticals
Last refreshed: 27 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06269133.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing